Construction and expression of a recombinant eukaryotic expression plasmid containing the preS1‑preS2‑S genes of hepatitis B virus and the granulocyte-macrophage colony stimulating factor gene: A study of its immunomodulatory effects
- Authors:
- Published online on: December 10, 2012 https://doi.org/10.3892/br.2012.47
- Pages: 251-256
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
Abstract
A total of 10‑20% of the population remains unresponsive or weakly responsive to hepatitis B vaccine, which is composed of hepatitis B surface antigen HBsAg (S protein). Therefore, it is necessary to develop a hepatitis B vaccine with a better penetrating and responsive rate. In the present study, a plasmid pVAX1‑L‑GM was constructed and its immunomodulatory effect of as hepatitis B virus (HBV) DNA vaccine was analyzed through the immunization of BALB/c mice. Immune responses were measured after immunization by anti‑HBsAg, proliferation of splenocytes, the number of CD4+ and CD8+ molecules, CTL cytotoxicity, cytokines of IFN‑γ and IL‑2 secretion assays. Following the immunization, mice in the pVAX1‑L‑GM group produced antibody 2 weeks earlier compared to the control plasmid pVAX1 and pVAX1HBsAg groups and antibody levels showed significant differences. Enhanced HBsAg‑specific splenocyte proliferation as well as specific cytotoxic activities of splenic CTLs were also detected. Furthermore, pVAX1‑L‑GM plasmid increased the number of CD4+ and CD8+ molecules on the surface of the spleen T cell and the level of IFN‑γ, IL‑2 secretion. pVAX1‑L‑GM induced a specific immune response in mice and enhanced the immune effect. Thus, a foundation was laid for developing immunogenicity of a better prevention and treatment of HBV via a hepatitis B vaccine.
